Western Firms Prepare to Exploit Chinese Reimbursement Reform
This article was originally published in PharmAsia News
Executive Summary
Western drugmakers are positioning themselves to exploit a multi-billion dollar healthcare reform program outlined by the Chinese government late last year
You may also be interested in...
Over There: Sanofi-Aventis Details Plans for Emerging Markets
Citing a "competitive advantage," Sanofi aims to double sales in new markets from €6.5 billion in 2008 to €17 billion by 2013.
Chinese Premier Wen Jiabao Allocates Healthcare Investment, But Essential Drug List Delayed Again
SHANGHAI - China's State Council issued additional healthcare reform plans July 8 to detail the goals of the country's ambitious reform plan. However, the release of the long-awaited essential drug list will be delayed to the end of this year, which was expected to be issued by June
More Investment In China’s Health Care System Unveiled During NPC; Is It Time To Ask Who Will Benefit First And Most?
SHANGHAI - With the world economy in a downturn, the annual session of China's National People's Congress, one of the most important meetings in the country, is being held in Beijing